No. 1 Potential GNPX Driver Indicator
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. These data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The TUSC2 gene is a tumor suppressor gene and is the active agent in REQORSA.
Read the full article here.
No. 2 Potential GNPX Driver Indicator
Genprex to Receive Inaugural "License of the Year" Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today that the Company has been selected to receive the inaugural "License of the Year" award from the University of Pittsburgh Innovation Institute (UPII) in recognition of the advances made with its license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes.
In February 2020, Genprex signed an exclusive license agreement with the University of Pittsburgh for an innovative gene therapy technology developed by lead researcher, George Gittes, M.D. at the Rangos Research Center at the University of Pittsbugh Medical Center ("UPMC") Children’s Hospital. The diabetes gene therapy candidate, GPX-002, which is being evaluated in preclinical studies, reprograms alpha cells in the pancreas into functional beta-like cells, thereby replenishing levels of insulin and providing the potential to cure the disease. The novel infusion is by means of an endoscopic procedure that delivers Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system.
"We thank the UPII for acknowledging the breakthrough work of Dr. George Gittes and his team at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, whose efforts have produced this highly innovative therapeutic approach to treating diabetes that could replace the need for insulin replacement therapy and ultimately lead to a cure of this devastating illness afflicting tens of millions of people around the world," said Rodney Varner, President and Chief Executive Officer of Genprex. "We are honored to receive this recognition, considering the great number of cutting-edge technologies coming out of this distinguished university and research center. We thank UPII for bestowing this honor on our gene therapy license with Dr. Gittes and the Rangos Research Center and applaud them for the groundbreaking gene therapy research being conducted at this esteemed institution."
Read the full article here.
No. 3 Potential GNPX Driver Indicator
According to MarketBeat, in January of 2021, National Securities initiated coverage on GNPX.
At the same time, they tagged this profile with a $7.00 price target and a "BUY" rating.
From Monday's close of $3.79, this target give GNPX upside potential of approximately 84%.
Now, that's not to say that GNPX is going to go soaring to $7.00 today, but I want you to be aware of the potential upside this firm has provide on this past champ.
No. 4 Potential GNPX Driver Indicator
According to Yahoo Finance, GNPX currently has an approximate 33.71Mn shares in its float.
As we've seen in previous stock profiles, including this one when I brought it to you back in February 2020 (approximately 336% surge in roughly two weeks) and July 2020 (approximately 30% in 2 days), a low float can lead to explosive vertical surges in the short-term due to possible volatility.
Biotech stocks can be very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.
Could the next big news coming from the GNPX camp be the spark to vertical run?
More About The Company: Genprex, Inc.
From the company website:
Our mission is to develop life-changing gene therapies for patients with cancer and diabetes through unique, innovative science.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and diabetes.
The company’s lead product candidate, REQORSA™ immunogene therapy (quaratusugene ozeplasmid), is being developed for non-small cell lung cancer (NSCLC). The active ingredient in REQORSA is the TUSC2 gene, a tumor suppressor gene. REQORSA uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of NSCLC. GPX-002, a gene therapy for diabetes, is the most recent addition of our licensed technologies.
Top GNPX Potential Driver Indicators Recap
#1. Positive Preclinical Data News
#2. "License Of The Year" Award From The University Of Pittsburgh Innovation Institute
#3. Analyst Coverage/Price Target
#4. Low Float/Possible Volatility
If there are any updates today, I'll get them out to you quickly.
(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)